IMpower133: Updated overall survival (OS) analysis of first-line (1L) atezolizumab (atezo) + carboplatin + etoposide in extensive-stage SCLC (ES-SCLC)
M. Reck, Stephen V. Liu(Georgetown University), Aaron S. Mansfield(Mayo Clinic in Arizona), Tony Mok(Chinese University of Hong Kong), Arnaud Scherpereel(Inserm), Niels Reinmuth(Asklepios Fachkliniken München-Gauting), Marina Chiara Garassino(Fondazione IRCCS Istituto Nazionale dei Tumori), J. De Castro Carpeño(Hospital Universitario La Paz), Raffaele Califano(The Christie NHS Foundation Trust), Makoto Nishio(The Cancer Institute Hospital), Francesco Orlandi(Instituto Nacional del Tórax), Jorge Arturo Alatorre Alexander, Ticiana Leal(University of Wisconsin Carbone Cancer Center), Ying Cheng(Jilin Province Tumor Hospital), J.-S. Lee(Seoul National University Bundang Hospital), S. Lam, Mark L. McCleland, Yu Deng, S. Phan, Leora Horn(Vanderbilt University Medical Center)
Cited by 68Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis